Boston, Massachusetts Feb 12, 2026 (Issuewire.com) - Andarix Pharmaceuticals, a clinical-stage biotechnology company pioneering targeted peptide therapies for rare cancers, today announced that Chris Adams, Founder and CEO, will be a featured speaker at the upcoming Outsourcing in Clinical Trials (OCT) West Coast conference. The event will take place in Burlingame, California, from February 11-12, 2026.
The OCT West Coast conference is a premier industry gathering focused on the operational challenges and innovative solutions within clinical development. This years program emphasizes the integration of advanced imaging and AI in clinical trials, a core component of the Andarix precision medicine platform.
Mr. Adams will deliver a presentation titled "Optimizing Clinical Operations for Targeted Radiopharmaceuticals". His session will discuss strategies for navigating the unique logistical and regulatory complexities of radiopharmaceutical trials, including the coordination of companion diagnostics and the supply chain for short-lived therapeutic isotopes.
The OCT West Coast conference provides an essential forum for clinical leaders to address the hurdles of modern oncology research, said Chris Adams, CEO of Andarix Pharmaceuticals. I look forward to discussing how precision targeting and integrated imaging can not only improve patient selection but also streamline the execution of complex clinical trials for underserved cancer populations.
Andarix continues to gain momentum with its proprietary peptide-targeted radionuclide technology, which leverages somatostatin analogs to deliver diagnostic and therapeutic radioisotopes directly to solid tumors, specifically targeting lung, pancreatic, and neuroendocrine cancers.
For more information about the OCT West Coast conference or to register, please visit the official conference website.
About Andarix Pharmaceuticals
Andarix Pharmaceuticals is at the forefront of personalized cancer therapy, developing next-generation targeted radiotherapeutics for oncology. The companys proprietary platform utilizes somatostatin peptide conjugates to enable a "theranostic" approachidentifying patients through diagnostic imaging and delivering high-energy radiotherapy directly to tumor cells while sparing healthy tissue. Headquartered in Somerville, MA, Andarix is dedicated to improving outcomes for patients with hard-to-treat and rare cancers.
Media Contact: Andarix Pharmaceuticals 617-957-9858 [email protected] www.andarix.com
Source :Andarix Pharmaceuticals
This article was originally published by IssueWire. Read the original article here.
